Novartis said that the Ministry of Food and Drug Safety has approved Scemblix (Ingredient: asciminib), a treatment for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).Semblix treats adult patients with Ph+ CML in the chronic stages who have received treatment
Hanmi Pharmaceutical said Wednesday that the number of its drugs under development that have won orphan drug designations (ODD) has increased to 20, breaking its own record in the Korean biopharmaceutical industry.Most recently, Hanmi received an ODD from the European Medicines Agency (EMA) for LAPS
List Biotherapeutics, a U.S. subsidiary of Genome & Company, said that it has started the construction of its microbiome treatment production facility in Fishers City, Ind.Established in October 2020, List Biotherapeutics plans to build a large-scale microbiome production facility in Fishers Life Sc
Celltrion Pharmaceutical said it would exclusively market two diabetes treatment lineups – Nesina and Actos – it took over from Takeda Pharmaceutical. Jeil Pharmaceutical has marketed the two treatments.Celltrion has decided to end the joint sales contract at the end of this month and start direct s
Korea AI Center for Drug Discovery and Development (KAICD) said Wednesday that it would recruit expert instructors to develop and teach artificial intelligence (AI) to facilitate drug discovery and practical cooperative research.As an affiliated organization of the Korea Pharmaceutical and Bio-Pharm
The number of patients registered for phase 3 clinical trials of GNT Pharma’s stroke treatment, Nelonemdaz, has exceeded 100, raising expectations for completing all related trials in 2023 as scheduled, the company said Tuesday.Nelonemdaz is the first drug candidate worldwide that received approval
Amgen Korea and Jeil Pharmaceutical said they signed an agreement to jointly sell Repatha (evolucumab), lipid-lowering drugs for atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia starting in June.Under the agreement, Amgen Korea and Jeil Pharmaceutical will conduct Repatha sale
CHICAGO, Ill. – Lilly’s VEGRF2 inhibitor Cyramza (ramucirumab) in combination with Keytruda (pembrolizumab) proved a survival benefit, compared with the existing chemotherapy-based standard of care, in patients with non-small cell lung cancer (NSCLC) whose disease progressed after the first-line imm
CHICAGO, Ill. – Pfizer’s first CDK4/6 inhibitor Ibrance (palbociclib), failed to extend overall survival (OS) in the first breast cancer treatment in the phase 3 PALOMA-2 study.However, the PALOMA-2 study was not designed to check OS data, and it did not include some survival data of patients during
Samsung Bioepis presented new data on its adalimumab biosimilar, IMRALDI (SB5), at the European Alliance of Associations for Rheumatology (EULAR) 2022, in Copenhagen, Denmark, on Wednesday.The phase 1 clinical trial demonstrated pharmacokinetic (PK) equivalence between the new SB5 formulation and th
Hugel said Friday it obtained marketing approval for Letybo 50Unit, a botulinum toxin (BTX), from Poland’s Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) on May 25.Earlier in 2019, Hugel and Austrian pharmaceutical firm Croma began phase 3 trials of the B
PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) could cure polycythemia vera (PV) fundamentally, the latest study results showed. Still, health experts said that Korean patients find it difficult to use it due to the lack of health insurance coverage.PharmaEssentia Korea held a symposium on
Pfizer Pharmaceuticals Korea has emphasized the importance of pneumococcal vaccination, especially for menopausal women, at a recent "Vxpert” (Vaccine + Expert) webinar.Pfizer Korea designed the event to highlight the risk of infectious diseases caused by reduced immunity in menopausal women and sha
Daewoong Pharmaceutical held a live seminar for dermatologists at nine branches of Doctors Dermatology Clinic nationwide to share various procedures using Daewoong’s Nabota and V-OLET products.Nineteen dermatologists attended the seminar to share their experiences and know-how.Sung Hyun-chul, direct
AbbVie is expected to top the annual prescription sales among pharmaceutical companies in 2028, thanks to growing sales of psoriasis drug Skirizi even after the expiration of blockbuster drug Humira’s patent, an industry report said.Evaluate Pharma, a global market research firm, announced the list
Global Clinical Central Lab (GCCL), a subsidiary of GC Cell, said it would provide an analysis service of neutralizing antibodies of vaccines and therapeutic agents for infectious viral diseases from June.Only specialized institutions equipped with biosafety knowledge and analytical technology can p
Hanmi Pharmaceutical will likely dominate the erectile dysfunction treatment market, divided into sildenafil (original: Viagra) and tadalafil (original: Cialis).The company has led the sildenafil market with Palpal, a Viagra generic, and is almost claiming the largest market share for tadalafil, mar
HK inno.N said that it had signed a business agreement with Ilias Biologics to research exosome-based new drug candidates jointly.Under the accord, the two companies plan to work closely together to discover new drug candidates using exosomes, attracting attention as a next-generation drug delivery
Hanmi Pharmaceutical said it has incorporated Spectrum, its U.S. partner, into an affiliate company ahead of commercializing its new drugs globally.Hanmi invested about 24 billion won ($19.1 million) in Spectrum earlier this year to expand its stake in the latter to 8.6 percent. Although the stake d
Daewoong Pharmaceutical’s sales of prescription drugs have expanded significantly this year.In April, Daewoong’s revenue from prescription drugs exceeded 70 billion won ($55.69 million).Accumulated sales in the first four months of 2022 recorded 267.5 billion won, up 14.3 percent from the same perio